Infixion Bioscience Inc.

Escondido, CA

UEI
F6B4DQXKDSE8
CAGE
855B9
Primary NAICS
541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
SAM.gov registration
Active through

Company facts

Self-certified in SAM.gov
  • For Profit Organization
Entity structure
Corporate Entity (Not Tax Exempt)
SAM.gov registration date
Physical address
2435 Carroll Ln, Escondido, CA 92027, USA
Website
infixionbio.com
Founded
2017
Employees
1-10
Estimated annual revenue
$0-$1M
Industry
  1. Health Care
  2. Pharmaceuticals, Biotechnology & Life Sciences
  3. Pharmaceuticals
SIC code
28 Chemical & Allied Products
Profiles

Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .

Grant awards

Award Agency Obligated Awarded
Selection of a lead candidate for the development of an ASO therapeutic for NF1 cognitive and social deficits… R43NS147645 National Institute of Neurological Disorders and Stroke (NIH) $478,799
Steric-blocking antisense oligonucleotide (ASO) discovery to selectively correct NF1 haploinsufficiency R43NS127718 National Institute of Neurological Disorders and Stroke (NIH) $1,656,193
Inhibition of NF1 protein degradation as a treatment for NF1 haploinsufficiency R43NS124424 National Institute of Neurological Disorders and Stroke (NIH) $1,303,728
Increasing NF1 expression as a treatment for NF1 haploinsufficiency R43NS117234 National Institute of Neurological Disorders and Stroke (NIH) $1,069,294

Grant subawards

Prime recipient Prime award Amount Awarded
The General Hospital Corporation Specific Aim 2 Develop CRISPRa Reagent - Major Task 1 Generation and Screen of CRISPRa reagents o Subtask 1 Modification of HiBit Screening line â–ª… HT94252310490 $267,056

Similar vendors

Vendor Location Primary NAICS
Quiver Bioscience Inc. UEI L9HHRYCBMBZ1 Cambridge, MA 541714 Research and Development in Biotechnology (except Nanobiotechnology)
Modulo Bio, Inc. UEI U1TNJGPGNHA9 San Diego, CA —
Psychogenics Inc. UEI YXMNA8N7LFG4 Paramus, NJ 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Artery Therapeutics, Inc. UEI JHVKQN55S7Y5 San Ramon, CA 541714 Research and Development in Biotechnology (except Nanobiotechnology)
Accounting UEI NNJ6BMBTFGN5 San Diego, CA 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

See more similar vendors on GovTribe

About the company

Written by GovTribe AI ·

Infixion Bioscience Inc., based in Escondido, California, receives federal research funding as a prime recipient under the National Institutes of Health's Small Business Innovation Research (SBIR) program, focused on antisense oligonucleotide (ASO) therapeutic discovery for neurological and genetic disorders. The vendor operates exclusively in the federal research grant space; it holds no federal contracts as a prime or subcontractor and carries no contract vehicles.

Infixion's federal footprint centers on the National Institute of Neurological Disorders and Stroke (NINDS) under CFDA 93.853 (Extramural Research Programs in the Neurosciences and Neurological Disorders). The vendor holds four prime SBIR grants focused on neurofibromatosis Type 1 (NF1) therapy development. The most recent award, dated September 1, 2026, totals $478,799 over two years (September 2026 through August 2028) and targets the development and selection of a lead-candidate ASO therapeutic to address cognitive and social deficits associated with NF1 by increasing NF1 protein levels and normalizing RAS hyperactivation. An earlier NINDS SBIR award dated September 1, 2022 (completion February 28, 2025) supported steric-blocking ASO discovery to correct NF1 haploinsufficiency. Performance of all NINDS work takes place in San Diego, California. The vendor also receives one sub-award from The General Hospital Corporation (dated October 17, 2024) as a sub-recipient under a parallel NF1 CRISPRa research grant, where Infixion provides NF1-HiBit Schwann cell lines and conducts screening work on CRISPRa reagents and in vivo candidate validation.

NINDS accounts for 100% of the vendor's customer concentration, with four awards totaling the entire $4.8 million combined obligated value across the portfolio. One additional award from the Defense Health Agency appears in the source data. Activity is sparse and episodic — one award per year in 2020, 2021, and 2022, then a single award in 2024 and a single award in 2026 — with one award (the February 2025 completion) reaching ultimate completion within the next twenty-four months and facing potential recompete. Infixion's capability portfolio is narrowly specialized: antisense oligonucleotide chemistry, microRNA targeting, CRISPR activation (CRISPRa) delivery, and in vivo validation in mouse models for genetic disorder therapeutics development, with exclusive focus on neurology and genetic disease phenotypes.

Quick answers

Is Infixion Bioscience Inc. registered in SAM.gov?

Yes. Infixion Bioscience Inc.'s SAM.gov registration is active through July 31, 2027.

What is Infixion Bioscience Inc.'s most recent federal award?

Infixion Bioscience Inc.'s most recent federal grant award is Selection of a lead candidate for the development of an ASO therapeutic for NF1 cognitive and social deficits… (R43NS147645), from National Institute of Neurological Disorders and Stroke (NIH), on September 1, 2026.

On GovTribe

See Infixion Bioscience Inc.'s full federal record

  • Federal grant awards
  • Funding analysis by agency, NAICS and set-aside
  • Similar vendors
Try for free Login